SCHEMBL31163043

SCHEMBL31163043

COc1cc(Cl)cc(Nc2ncc(C)c(Nc3cccc(S(=O)(=O)NC(C)(C)C)c3)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 7/20 0.62
▸ BRD4 O60885 10/20 0.60
▸ JAK1 P23458 9/20 0.60
▸ JAK3 P52333 6/20 0.60
▸ TYK2 P29597 4/20 0.60
▸ RET P07949 3/20 0.60
▸ WEE1 P30291 3/20 0.60
▸ FLT3 P36888 3/20 0.60
▸ ALK Q9UM73 3/20 0.60
▸ BRDT Q58F21 2/20 0.60
▸ NUAK1 O60285 2/20 0.60
▸ PLK4 O00444 2/20 0.60
▸ CHEK1 O14757 2/20 0.60
▸ AURKA O14965 2/20 0.60
▸ DCLK1 O15075 2/20 0.60
▸ DAPK3 O43293 2/20 0.60
▸ ROCK2 O75116 2/20 0.60
▸ PAK4 O96013 2/20 0.60
▸ ABL1 P00519 2/20 0.60
▸ EGFR P00533 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30565216 0.94 JAK2 (0.67) JAK2BRD4JAK1JAK3TYK2
SCHEMBL25381399 0.94 JAK2 (0.67) JAK2BRD4JAK1JAK3TYK2
SCHEMBL31163131 0.90 JAK2 (0.62) JAK2BRD4JAK1JAK3TYK2
SCHEMBL20288209 0.88 JAK2 (0.75) JAK2BRD4JAK1JAK3TYK2
SCHEMBL30565204 0.87 BRD4 (0.74) JAK2BRD4JAK1JAK3TYK2
SCHEMBL30565206 0.87 BRD4 (0.74) JAK2BRD4JAK1JAK3TYK2
SCHEMBL25382998 0.87 BRD4 (0.74) JAK2BRD4JAK1JAK3TYK2
SCHEMBL31163087 0.85 JAK2 (0.63) JAK2BRD4JAK1JAK3TYK2
SCHEMBL13031088 0.84 BRD4 (0.73) JAK2BRD4JAK1JAK3TYK2
SCHEMBL31163079 0.84 JAK2 (0.66) JAK2BRD4JAK1JAK3TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673149-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA Trustlife Global Inc. (US) 2026-01-07 — — EP disclosed
WO-2024179699-A1 NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA BASH BIOTECH INC. (US) 2024-09-06 — — WO disclosed
Send feedback